home / stock / crmd / crmd news

CRMD News and Press, CorMedix Inc. From 05/13/19

Stock Information
Company Name: CorMedix Inc.
Stock Symbol: CRMD
Market: NYSE
Website: cormedix.com
Menu
CRMD CRMD Quote CRMD Short CRMD News CRMD Articles CRMD Message Board
Get CRMD Alerts

News, Short Squeeze, Breakout and More Instantly...
CRMD - CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2019 Results - Earnings Call Transcript

CorMedix, Inc. (CRMD) Q1 2019 Results Earnings Conference Call May 13, 2019, 04:30 PM ET Company Participants Dan Ferry - IR-LifeSci Advisors Khoso Baluch - CEO Bob Cook - CFO Phoebe Mounts - EVP and General Counsel Paul Chew - Chief Medical Officer Conference Call Partic...
CRMD - CorMedix beats by $0.06, beats on revenue

CorMedix (NYSEMKT: CRMD ): Q1 GAAP EPS of -$0.22 beats by $0.06 . More news on: CorMedix, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CRMD - CorMedix Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results...

CRMD - Cormedix Announces Presentation of LOCK-IT-100 Study Results at National Kidney Foundation Spring 2019 Meeting

BERKELEY HEIGHTS, N.J., May 10, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, is pleased to announce that the r...
CRMD - CorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update on May 13

BERKELEY HEIGHTS, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will repo...

CRMD - CorMedix: Infected With Hype, Valuation Swollen

We believe CorMedix ( CRMD ) represents the classic case of an extremely overvalued small-cap biotech due to a large and enthusiastic retail shareholder base greatly overestimating a market opportunity. At the same time, in the next several months a critically important binary event is due - t...

CRMD - CorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meeting of American Society of Clinical Oncology

BERKELEY HEIGHTS, N.J., April 22, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced publication onl...
CRMD - CorMedix completes sale of $5.4M of NOL tax benefits

CorMedix (NYSEMKT: CRMD ) has completed the sale of $5.4M of NOL tax benefits to two New Jersey corporations. More news on: CorMedix, Inc., Healthcare stocks news, Read more ...

CRMD - CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program

BERKELEY HEIGHTS, N.J., April 17, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has com...

CRMD - CorMedix Notified of Compliance with NYSE American Listing Requirements

BERKELEY HEIGHTS, NJ / ACCESSWIRE / April 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that on Friday, April ...
Previous 10 Next 10